ArticleEuropean journal of heart failure2022
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality.
Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07623083 (Evaluation of a Treatment Algorithm for the Management of TAVI Patients With Significant Concomitant Mitral or Tricuspid Regurgitation), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of a Treatment Algorithm for the Management of TAVI Patients With Significant Concomitant Mitral or Tricuspid Regurgitation
Who cites it
34 citing papers in PubMed, 63 citations in OpenAlex.
- One-Stop Dual-Valve Transcatheter Intervention: Simultaneous Mitral TEER and K-Clip Tricuspid Annuloplasty.Anatolian journal of cardiology · 2026Article
- Persistent Severe Tricuspid Regurgitation After Mitral Transcatheter Edge-to-Edge Repair: Prognostic Implications of Guideline-Based Eligibility for Transcatheter Tricuspid Valve Intervention.Structural heart : the journal of the Heart Team · 2026Article
- The impact of residual tricuspid regurgitation on long-term clinical outcomes, following tricuspid transcatheter edge-to-edge repair.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Prognosis of tricuspid regurgitation after mitral transcatheter edge-to-edge repair: the EXPANDed studies.ESC heart failure · 2026Observational
- Worsening tricuspid regurgitation following a successful mitral valve procedure: how to manage.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Aetiology, prevalence, and prognosis.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Why we need treatment? Prognosis of tricuspid regurgitation.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Transcatheter and surgical management of tricuspid valve disease: multidisciplinary lifetime management considerations.Annals of cardiothoracic surgery · 2026Review
- Tricuspid regurgitation and right ventricular dysfunction: preoperative non-procedural interventions to improve procedural outcomes.Annals of cardiothoracic surgery · 2026Article
- Impact of Transcatheter Mitral and Tricuspid Valve Repair on Hepatic Function and Outcomes in Patients with Cirrhosis or Advanced Liver Disease-A Personalized Approach.Journal of clinical medicine · 2026Review
- Interplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper.ESC heart failure · 2026Review
- Right Ventricular Function in Patients With Significant Tricuspid Regurgitation.Reviews in cardiovascular medicine · 2026Review
- Article
- Combined MitraClip and TriClip therapy in patients with severe mitral and tricuspid regurgitation: determinants and prediction of mid-term outcomes.Frontiers in cardiovascular medicine · 2026Article
- Prognostic Impact of Modified J-MACS Score in Patients With Systolic Heart Failure Receiving Transcatheter Edge-to-Edge Mitral Valve Repair.Journal of the American Heart Association · 2025Observational
- Impact of pulmonary hypertension dynamics and residual mitral regurgitation shortly after M-TEER on long-term outcomes: insights from a prospective registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Tricuspid Regurgitation: A Comprehensive Review of Clinical, Imaging and Therapy.Reviews in cardiovascular medicine · 2025Review
- Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.European heart journal · 2025Observational
- Clinical Characteristics, Outcomes, and Risk Stratification of Combined Mitral and Tricuspid Regurgitation: The China-VHD Study.JACC. Asia · 2025Article
- 2024 update in heart failure.ESC heart failure · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 16 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate short-term changes in tricuspid regurgitation (TR) after transcatheter edge-to-edge mitral valve repair (M-TEER) in secondary mitral regurgitation (SMR), their predictors and impact on mortality. METHODS AND
resultsThis is a retrospective analysis of SMR patients undergoing successful M-TEER (post-procedural mitral regurgitation ≤2+) at 13 European centres. Among 503 patients evaluated 79 (interquartile range [IQR] 40-152) days after M-TEER, 173 (35%) showed ≥1 degree of TR improvement, 97 (19%) had worsening of TR, and 233 (46%) remained unchanged. Smaller baseline left atrial diameter and residual mitral regurgitation 0/1+ were independent predictors of TR ≤2+ after M-TEER. There was a significant association between TR changes and New York Heart Association class and pulmonary artery systolic pressure decrease at echocardiographic re-assessment. At a median follow-up of 590 (IQR 209-1103) days from short-term echocardiographic re-assessment, all-cause mortality was lower in patients with improved compared to those with unchanged/worsened TR (29.6% vs. 42.3% at 3 years; log-rank p = 0.034). Baseline TR severity was not associated with mortality, whereas TR 0/1+ and 2+ at short-term follow-up was associated with lower all-cause mortality compared to TR 3/4+ (30.6% and 35.6% vs. 55.6% at 3 years; p < 0.001). A TR ≤2+ after M-TEER was independently associated with a 42% decreased risk of mortality (p = 0.011).
conclusionMore than one third of patients with SMR undergoing successful M-TEER experienced an improvement in TR. Pre-procedural TR was not associated with outcome, but a TR ≤2+ at short-term follow-up was independently associated with long-term mortality. Optimal M-TEER result and a small left atrium were associated with a higher likelihood of TR ≤2+ after M-TEER.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.